Received Dec 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | X5FN4 | IM / LA |
high blood sugar; This non-serious case was reported by a pharmacist and described the occurrence of blood sugar increased in a 72-year-old male patient who received Herpes zoster (Shingrix) (batch number X5FN4, expiry date 17-JUN-2027) for prophylaxis. Concurrent medical conditions included diabetes. On 03-DEC-2025, the patient received Shingrix (intramuscular, left arm) .5 ml. On 03-DEC-2025, less than a day after receiving Shingrix, the patient experienced blood sugar increased (Verbatim: high blood sugar). The outcome of the blood sugar increased was unknown. It was unknown if the reporter considered the blood sugar increased to be related to Shingrix. It was unknown if the company considered the blood sugar increased to be related to Shingrix. Additional Information: GSK Receipt Date: 04-DEC-2025 The patient received a dose of Shingrix at a local pharmacy. The reporter reported that the patient contacted the pharmacy after being vaccinated and reported high blood sugar levels. The reporter attempted to contact the healthcare professional to clarify if the injection was the 1st or the 2nd dose of Shingrix, but she was not available. No additional information was provided.
Diabetes